Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.32 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6152354 | 0.90 | CCR3 (0.33) | CCR3BDKRB1KDM4EALDH1A1 | |
| SCHEMBL6153058 | 0.90 | CCR3 (0.33) | CCR3BDKRB1KDM4EALDH1A1 | |
| SCHEMBL6153060 | 0.89 | BDKRB1 (0.34) | CCR3BDKRB1KDM4EALDH1A1 | |
| SCHEMBL6153099 | 0.89 | CCR3 (0.33) | CCR3BDKRB1KDM4EALDH1A1 | |
| SCHEMBL6152996 | 0.87 | POLB (0.34) | CCR3KDM4EALDH1A1 | |
| SCHEMBL6152358 | 0.85 | BDKRB1 (0.32) | BDKRB1 | |
| SCHEMBL6943073 | 0.84 | CCR3 (0.37) | CCR3KDM4EALDH1A1 | |
| SCHEMBL6154565 | 0.84 | CCR3 (0.34) | CCR3KDM4EALDH1A1 | |
| SCHEMBL9080882 | 0.84 | SIGMAR1 (0.42) | CCR3KDM4EALDH1A1 | |
| SCHEMBL6154290 | 0.83 | CCR3 (0.35) | CCR3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307449-B1 | 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS | PFIZER PHARMA (JP) | 2005-12-07 | — | — | EP | disclosed |
| US-6653313-B2 | For treatment and prevention of inflammation, asthma, allergic rhinitis, pain and other disorders | WARNER-LAMBERT COMPANY LLC | 2003-11-25 | — | — | US | disclosed |
| EP-1307449-A1 | 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-20020161006-A1 | 1,4-dihydropyridine compounds as bradykinin antagonists | KAWAMURA MITSUHIRO (US) | 2002-10-31 | — | — | US | disclosed |
| WO-2002012235-A1 | 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161006-A1 | 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, HRH4 | CCR3 221/4885BDKRB1 1/4885KDM4E 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.